Sanofi will retain its insulin business, but will otherwise stop research and development in diabetes and cardiovascular drugs in order to focus on cancer immunotherapies and its biologic for asthma and allergies.
Sanofi will retain its insulin business, but will otherwise stop research and development in diabetes and cardiovascular drugs in order to focus on cancer immunotherapies and its biologic for asthma and allergies.
The announcement was made Monday by Paul Hudson, the company’s new chief executive officer, who said during a media call that “we as a company have probably done more than almost any other companies combined, to innovate and to transform lives in diabetes and cardiovascular. Now we need to be efficient and move our resources to areas of opportunity, unmet needs and to grow our pipeline.”
Lantus, the originator insulin glargine, is under pressure from follow-on competition, given the commercialization of Boehringer Ingelheim’s Basaglar, the first FDA-approved insulin glargine follow-on, which launched in 2016 after a lengthy patent litigation with Sanofi.
In addition, insulin as a whole has been in the center of a debate for more than a year about high drug prices. Lantus, along with Novolog and Humalog, have shown highly synchronized price increases, coinciding with some of the largest growth in drug costs. And patients have traveled to Capitol Hill to testify how the rising prices have forced them to skip doses or go without.
However, a company spokesman said Monday that Sanofi will retain a proposed biosimilar of insulin aspart (NovoLog) in its pipeline as a registration phase molecule. Data on SAR341402 was presented in 3 late-breaking poster presentations at the American Diabetes Association (ADA) 79th Scientific Sessions last June. While insulins are currently regulated as drugs and follow-ons in the US context, they will become regulated as biologics and biosimilars in March 2020.
The Wall Street Journal (WSJ) noted Monday that diabetes has been a key driver for Sanofi since 2004, when Aventis and Sanofi-Synthelabo merged. Aventis had launched Lantus 4 years prior. By 2004, it was already the most widely prescribed insulin in the country.
Lantus represents that largest share of Part D spending on insulin, according to an analysis by the Kaiser Family Foundation.
Sanofi is shifting to focus on immunotherapies in cancer treatment; the company will buy biotech Synthorx for $2.5 billion. Sanofi has fallen behind in the race to develop immunotherapies, according to the WSJ report.
In addition, it wants to focus on dupilumab (Dupixent), a drug for severe chronic rhinosinusitis with nasal polyposis, severe asthma, and moderate-to-severe atopic dermatitis. Sanofi thinks the drug could eventually generate $10 billion.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).
Biosimilars Business Roundup For August 2023—Podcast Edition
September 5th 2023On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.
AMCP Nexus: Panelists Share Current Scope of Biosimilar Industry
October 26th 2023Panelists at the Academy of Managed Care Pharmacy (AMCP) Nexus meeting chronicled the current state of the US biosimilar market, including current policies impacting the market, recent regulatory decisions, and the developing arguments around requirements for clinical efficacy studies.
Report: Conflicting Guidelines, Rebate Walls Are Major Factors Determining Biosimilar Uptake
October 24th 2023Samsung Bioepis’ most recent biosimilar market report identified inconsistent medical guidelines, challenges with access and rebates, and acute vs chronic treatment duration as major factors influencing biosimilar uptake in the United States.